TPST News and Press, Tempest Therapeutics Inc. From 07/19/23

In vitro and in vivo data show significant increased potency by blocking prostaglandin PGE2 signaling through both EP2 and EP4 receptors compared to celecoxib or single EP4 antagonists TPST-1495 anti-tumor response shown to be both immune dependent and immune independent Preclinic...

BRISBANE, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class 1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will present at the Jefferies Glo...

• Data show tumor shrinkage and prolonged disease control in both monotherapy and in combination with pembrolizumab • Oral, once-daily cancer treatment well tolerated with a manageable safety profile • Data to be reported at the 2023 ASCO Annual Meeting ...

BRISBANE, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class 1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that the Compensation Committee of the company&#x...

2023-05-10 17:28:26 ET Tempest Therapeutics press release ( NASDAQ: TPST ): Q1 GAAP EPS of -$0.55 beats by $0.07 . Tempest ended the first quarter with $22.9 million in cash and cash equivalents, compared to $31.2 million on December 31, 2022. For further details...

BRISBANE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class i therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended March 31, ...

2023-04-28 10:03:38 ET Gainers: Tempest Therapeutics ( TPST ) +72% . CVRx ( CVRX ) +25% . ImmunoGen ( IMGN ) +22% . Apyx Medical ( APYX ) +17% . bluebird bio ( BLUE ) +17% . Losers: Hillstream BioPharma ( HILS ) -56%...

2023-04-28 09:12:51 ET Tempest Therapeutics ( NASDAQ: TPST ) said its drug TPST-1120 showed clinically-meaningful improvement in multiple categories in patients with a type of liver cancer as per early data from a phase 1b/2 trial. The phase 1b/2 global study is part of Roc...

Positive randomized data with TPST-1120 combined with atezolizumab + bevacizumab compared head-to-head with atezolizumab + bevacizumab The addition of TPST-1120 resulted in a clinically-meaningful improvement in both confirmed and unconfirmed RECIST responses The number of p...

BRISBANE, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class 1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced the company plans to report early data from its...